Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
DuRoss Amy reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Amy DuRoss received an award of 8,170 shares of Common Stock as restricted stock. The grant was made at no cash cost under the BioLife Solutions 2023 Performance Incentive Plan and will fully vest on the first anniversary of the vesting date of January 2, 2026. After this award, DuRoss directly holds 26,857 common shares.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported equity compensation and related tax withholding transactions in company stock. On February 24, 2026, he acquired 31,150 shares and 64,866 shares of restricted common stock at $0 per share as grants under the 2023 Omnibus Performance Incentive Plan.
The first grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The second grant vested at approximately 156% of the target number of shares based on total shareholder return from January 1, 2024 through December 31, 2025 versus a peer group. To cover tax withholding on the vested market-based award, 25,525 shares were disposed of at $22.65 per share. Following these transactions, Wichterman directly held 221,237 shares of common stock.
Hunt Anthony reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Anthony Hunt received a grant of 8,170 shares of common stock as a restricted stock award. The award was made at no cash cost per share and increased his directly held common stock to 15,046 shares following the transaction. According to the footnote, the restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026."
Coste Catherine reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Catherine Coste reported an equity award of 8,170 shares of common stock as a grant under the BioLife Solutions 2023 Performance Incentive Plan. The restricted stock was granted at no cash price and will fully vest on the first anniversary of the vesting date of January 2, 2026. Following this award, Coste beneficially owns 13,871 common shares directly.
Ellingson Rachel reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Rachel Ellingson reported receiving a grant of 8,170 shares of restricted common stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These shares were granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the terms, fully vest on the first anniversary of the vesting date of January 2, 2026. Following this grant, Ellingson directly holds a total of 57,995 shares of BioLife Solutions common stock.
BioLife Solutions President and CEO Roderick De Greef reported several equity awards and related tax withholdings. On February 24, 2026, he acquired three blocks of restricted common stock totaling 118,730, 170,291 and 219,024 shares at a stated price of $0.00 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan, including 2026 compensation that vests 25% on the first anniversary and then in 12 equal quarterly installments. Other restricted stock vested based on total shareholder return from January 1, 2024 to December 31, 2025 versus peers and on specific performance metrics, leading to vesting at approximately 156% and 200% of target.
To satisfy tax withholding obligations on the market‑ and performance‑based vesting, 67,010 and 86,186 shares were disposed of at $22.65 per share through share withholding rather than open‑market sales. After these transactions, De Greef directly held 744,847 shares of BioLife Solutions common stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported equity awards and related share withholding in company stock. He acquired 20,096 shares of restricted common stock and 39,605 shares of market-based restricted stock on February 24, 2026 at a stated price of $0.0000 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan as part of 2026 compensation. One grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The market-based award vested at approximately 156% of the original grant based on relative total shareholder return versus selected peers from January 1, 2024 through December 31, 2025.
To cover tax withholding obligations on the vesting of the market-based award, 15,585 shares were withheld at $22.65 per share. Following these transactions, Mathew Aby J. directly owns 393,466 shares of BioLife Solutions common stock.
BioLife Solutions Chief Human Resources Officer Sarah Aebersold received a grant of 23,548 shares of common stock at $0.00 per share, tied to the company’s 2023 Omnibus Performance Incentive Plan. About 156% of the target shares vested based on relative total shareholder return, and 5,734 shares were withheld at $22.65 per share to cover taxes, leaving her with 93,579 shares directly owned.
Werner Sean reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Chief Technology Officer Sean Werner received a grant of 24,116 shares of common stock as part of his 2026 compensation. The restricted stock was issued under the 2023 Omnibus Performance Incentive Plan and will vest 25% on the first anniversary of the grant date, then in 12 equal quarterly installments. Following this award, he directly holds 50,043 shares of common stock.
MOORE TIMOTHY L. reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Timothy L. Moore received a grant of 8,170 shares of restricted common stock. The award was made at a stated price of $0.0000 per share and was granted under the BioLife Solutions 2023 Performance Incentive Plan.
According to the filing, these restricted shares will fully vest on the first anniversary of the vesting date of January 2, 2026. After this grant, Moore directly holds a total of 44,943 shares of BioLife Solutions common stock.